Regeneron Starts Phase 3 Trial For Coronavirus Antibody Cocktail

Regeneron Pharmaceuticals has started late-stage clinical trials evaluating REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of COVID-19. A Phase 3 trial will evaluate REGN-COV2's ability to prevent infection among uninfected people who have had close exposure to a COVID-19 patient.

Publisher: Contract Pharma | Author:

TAGS
antibody, prevention, and treatment
DATE PUBLISHED
2020-07-06 (Modified: 2021-09-20)

STAR RATING
VIEW RESOURCE
https://www.contractpharma.com/contents/view_breaking-news/2020-07-06/regeneron-starts-phase-3-trial-for-coronavirus-antibody-cocktail/

Leave a Reply